The ROAR trial also evaluated the dabrafenib–trametinib combination in BRAF V600E-mutated rare tumors, including high-grade and low-grade gliomas, showing a 54% ORR in low-grade glioma (LGG) and a 33% ORR in high-grade glioma (HGG), suggesting superior efficacy over vemurafenib alone [19] (Figure 2). This evidence concerns the gene BRAF and central nervous system cancer.